<DOC>
	<DOCNO>NCT02231346</DOCNO>
	<brief_summary>New perception handle patient satisfaction everyday use Berodual® Respimat® compare powder inhaler patient chronic obstructive lung disease ( COLD ) . Moreover , knowledge attain tolerability Berodual® Respimat®</brief_summary>
	<brief_title>Postmarketing Surveillance Study Assess Handling Patient Satisfaction Berodual® Respimat® Solution Inhalation Comparison Powder Inhaler Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Male female patient age least 18 year Patients suffer symptom chronic obstructive lung disease ( COLD ) include PMS . To reduce influence cause use variety different powder inhaler , patient already regularly use Diskus® powder inhaler include , Diskus® well Berodual® Respimat® multiple dose device During PMS Diskus® therapy continue Patients meet one general specific contraindication mention Summary Product Characteristics ( SmPC ) exclude Postmarketing Surveillance ( PMS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>